Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain

Respiratory syncytial virus (RSV) vaccines primarily focused on surface fusion (F) protein are under development. Therefore, to identify RSV‐F protective epitopes, we evaluated 14 antigenic sites recognized following primary human RSV infection. BALB/c mice were vaccinated with F peptides, F proteins, or RSV‐A2, followed by rA2‐Line19F challenge. F peptides generated binding antibodies with minimal in vitro neutralization titers. However, several F peptides (including Site II) reduced lung viral loads and lung pathology scores in animals, suggesting partial protection from RSV disease. Interestingly, animals vaccinated with peptides (aa 101–121 and 110–136) spanning the F‐p27 sequence, which is only present in unprocessed F0 protein, showed control of viral loads with significantly reduced pathology compared with mock‐vaccinated controls. Furthermore, we observed F‐p27 expression on the surface of RSV‐infected cells as well as lungs from RSV‐infected mice. The anti‐p27 antibodies demonstrated antibody‐dependent cellular cytotoxicity (ADCC) of RSV‐infected A549 cells. These findings suggest that p27‐mediated immune response may play a role in control of RSV disease in vivo, and F‐p27 should be considered for inclusion in an effective RSV vaccine.

[1]  A. Pollard,et al.  Priorities for developing respiratory syncytial virus vaccines in different target populations , 2020, Science Translational Medicine.

[2]  N. Patel,et al.  Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection. , 2019, Vaccine.

[3]  W. Martinet,et al.  Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity. , 2019, Virus research.

[4]  S. Khurana,et al.  Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains , 2018, PLoS pathogens.

[5]  M. Skwarczynski,et al.  Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein , 2017, Scientific Reports.

[6]  Young‐Tae Lee,et al.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles , 2017, Human vaccines & immunotherapeutics.

[7]  N. Patel,et al.  A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants , 2017, Science Translational Medicine.

[8]  S. Khurana,et al.  Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. , 2017, Vaccine.

[9]  S. Khurana,et al.  Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins , 2016, PLoS pathogens.

[10]  H. Schuitemaker,et al.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism , 2015, Nature Communications.

[11]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[12]  S. Khurana,et al.  Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. , 2013, Vaccine.

[13]  A. Helenius,et al.  Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein , 2013, PLoS pathogens.

[14]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[15]  B. Murphy,et al.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. , 1990, Vaccine.

[16]  R. Chanock,et al.  Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. , 1992, Vaccine.